Select a year:

4P-Pharma at BIO-Europe 2023

We are delighted to announce our upcoming BIO-Europe participation from November 6th to 8th in Munich!  Roselina Lam, our Business Development and Licensing-in Manager, is attending the event.   For more information about our pipeline or to schedule a meeting, contact us through our partnering platform: here

Read More

4Moving Biotech completes the recruitment of its Phase I clinical trial in patients with knee osteoarthritis

Our subsidiary, 4Moving Biotech, dedicated to facing the global challenge of knee osteoarthritis, announces that it has reached a significant milestone by completing patient recruitment for its LASARE Phase I clinical trial. The Phase I trial is designed as a multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of intra-articular injection&hellip

Read More

4P-Pharma at CHINA Bio 2023

We are pleased to announce our company’s participation at CHINA Bio 2023, from September 20 – 21, 2023, in Shanghai, China. Our Chairwoman, Revital Rattenbach, and our CEO, Didier Landais, and Francis Berenbaum, CEO/CMO of our subsidiary, 4Moving Biotech, will attend this event.   During the event, Pr. Francis Berenbaum will showcase our subsidiary, 4Moving&hellip

Read More

Didier Landais is appointed 4P-Pharma’s CEO

We are delighted to announce the appointment of Didier Landais as the CEO of 4P-Pharma. Didier Landais brings a wealth of experience and strategic leadership to our team. His dynamic vision and profound insights will drive 4P-Pharma into an era of innovation and growth. Find the press release in English here.

Read More

4P-Pharma au BIO US 2023

Meet us in Boston during the Bio US 2023, June 5th to 8th! Roselina Lam, our Business Development and Licensing-in Manager, will be participating at the event, part of the french healthcare delegation ! Schedule a meeting with us !  

Read More

4P-Pharma appoints Mathilde Mérot Director of Regulatory Affairs and Clinical Operations

4P-Pharma is delighted to welcome Mathilde Mérot appointed Director of Regulatory Affairs and Clinical Operations. She has ten years of experience and a background in Pharma and Biotech companies. Her expertise will complement ours to develop and bring curative therapies for serious untreated diseases to patients. About Mathilde Mérot Mathilde Mérot started her career in clinical&hellip

Read More